Recalled Medicines & supplements – Current GIS Alerts 2026
Found 698 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Atofab
Out-of-specification results for atomoxetine content and capsule mass uniformity (OOS) detected in reference tests. Potential effects: reduced efficacy of the medicine.
Atofab
Results out of specification (OOS) for atomoxetine content and non-uniformity of capsule mass in identified batches. Potential effects: reduced therapeutic efficacy.
Atofab
Out-of-specification results for atomoxetine content and non-uniform capsule mass caused by manufacturing defects and changed API particle properties. Potential effects: reduced efficacy of the medicine.
Corhydron 25
A quality defect was identified consisting of an out-of-specification result for free hydrocortisone content, with this exceedance expected to increase until the end of the shelf-life of batch 110021. Potential effects: reduced efficacy or unpredictable action of this life-saving emergency medicine.
Corhydron 25
An out-of-specification (OOS) result was found in stability testing for the free hydrocortisone content; further increase is expected until the end of shelf life of batch 110021, which may affect dissolution and the drug’s performance. Potential effects: reduced therapeutic efficacy or unpredictable effects of the injectable medicine.
Symibace
An exceedance of the specification limit for impurity B was found, which according to the authority represents a real and probable risk to human health. Potential effects: poisoning, complications, lack of treatment safety.
Symibace
It was found that the specification limit for contamination (Impurity B) in batch 49N013A was exceeded, which means failure to meet established quality requirements and represents a real and probable risk to patients’ health. Potential effects: adverse reactions, treatment complications, possible deterioration of health.
Faringan
Non-compliance with quality requirements was found: too low benzocaine content, exceeding acceptable limits of related substances (including a single unknown impurity), and excessive tablet crumbling in the friability test. Potential effects: reduced treatment efficacy, possible undefined toxicological risk, difficulties in taking crumbled tablets.
Faringan
non-compliance was found consisting in exceeding the lower limit of benzocaine content, exceeding the permissible limit of benzocaine-related substances (single unknown impurity and total impurities), and crumbling of tablets after abrasion resistance testing. Potential effects: lack of treatment efficacy, unknown risk from impurities, possible adverse effects.
Eptifab
Incorrect information in the leaflet was found: swapped dosing instructions for patients with normal and impaired renal function, which may lead to improper dosing of the injection solution and direct, serious health consequences. Potential effects: poisoning, severe bleeding complications, lack of treatment efficacy, life‑threatening events.
Vabysmo
Cracked blisters with needles with transfer filter were found, so the sterility of the needles and the solution for injection is not ensured; a class I defect, potentially life‑threatening for patients. Potential effects: infection, severe ophthalmic complications, life‑threatening conditions.
Vabysmo
Cracked blisters with needles with a transfer filter were identified in product packs, so sterility of the needles and the solution for injection is not ensured; the defect was classified as Class I, potentially life‑threatening or posing a serious health risk. Potential effects: severe intraocular infections, ophthalmic complications, sepsis, life‑threatening condition.
Gripblocker Express
The quality defect consists of cracking of the soft gelatin capsule seams and leakage of the filling into the blister pocket, creating a real risk to patients’ health due to the possibility of receiving an incomplete dose and lack of treatment effectiveness. Potential effects: lack of treatment efficacy, possible complications of the underlying disease.
Gripblocker Express
Cracking of the soft gelatin shell seams and leakage of the capsule fill into the blister pocket were found, creating a real risk to patients’ health through the possibility of taking an incomplete dose and lack of effectiveness of the medicinal product. Potencjalne skutki: lack of treatment effectiveness, worsening or prolongation of disease symptoms.
Maść szałwiowa
The lack of a correct authorization number on the packaging makes it impossible to verify if the product may be marketed in Poland and raises doubts about its authenticity. This situation may mislead users and poses a threat to public health. Potential effects: incorrect use of the medicine, lack of treatment efficacy, possible health complications.
Maść szałwiowa
The lack of a correct marketing authorisation number on the outer packaging makes it impossible to verify whether the product can be legally marketed in Poland and raises doubts about the authenticity of the medicine; it may mislead users, posing a threat to public health. Potential effects: inability to verify medicine authenticity, risk of using a product not compliant with its authorisation.
Konaten
Out-of-specification (OOS) results were found for atomoxetine content below the lower limit and, for one batch, non-compliant capsule mass uniformity, leading to a reduced dose of the medicine. Potential effects: reduced treatment efficacy, worsening of disease symptoms.
Konaten
for 7 of 41 batches marketed in Poland, out‑of‑specification results for atomoxetine content were found in reference samples, below the lower specification limit; the medical risk assessment indicated possible low effectiveness of the medicine. Potential effects: reduced therapeutic efficacy, risk of lack of the expected treatment effect.
Konaten
Out-of-specification (OOS) results were found for atomoxetine content, below the lower specification limit, and in one batch also non-compliance in the mass uniformity parameter. The risk assessment points mainly to a possibility of reduced treatment effectiveness. Potential effects: absence or reduction of therapeutic efficacy.
Konaten
For some batches reference samples showed out-of-specification atomoxetine content below the lower limit, and for one batch also non-compliant capsule mass uniformity. Potential effects: reduced treatment efficacy, risk of lack of therapeutic effect.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.